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Hong, Jia Guo, and Fuad N. Ziyadeh. Therapy with
antisense TGF-b1 oligodeoxynucleotides reduces kidney
weight and matrix mRNAs in diabetic mice. Am J Physiol
Renal Physiol 278: F628–F634, 2000.—Inhibition of gene
expression by antisense oligodeoxynucleotides (ODNs) relies
on their ability to bind complementary mRNA sequences and
prevent translation. The proximal tubule is a suitable target
for ODN therapy in vivo because circulating ODNs accumu-
late in the proximal tubule in high concentrations. Because
increased proximal tubular transforming growth factor- b1
(TGF-b1) expression may mediate diabetic renal hypertro-
phy, we investigated the effects of antisense TGF-b1 ODN on
the high-glucose-induced proximal tubular epithelial cell
hypertrophy in tissue culture and on diabetic renal hypertro-
phy in vivo. Mouse proximal tubular cells grown in 25 mM
D-glucose and exposed to sense ODN as control (1 µM)
exhibited increased 3[H]leucine incorporation by 120% and
total TGF-b1 protein by 50% vs. culture in 5.5 mM D-glucose.
Antisense ODN significantly decreased the high-glucose-
stimulated TGF-b1 secretion and leucine incorporation. Con-
tinuous infusion for 10 days of ODN (100 µg/day) was
achieved via osmotic minipumps in diabetic and nondiabetic
mice. Sense ODN-treated streptozotocin-diabetic mice had
15.3% increase in kidney weight, 70% increase in a1(IV)
collagen and 46% increase in fibronectin mRNA levels com-
pared with nondiabetic mice. Treatment of diabetic mice with
antisense ODN partially but significantly decreased kidney
TGF-b1 protein levels and attenuated the increase in kidney
weight and the a1(IV) collagen and fibronectin mRNAs. In
conclusion, therapy with antisense TGF-b1 ODN decreases
TGF-b1 production and attenuates high-glucose-induced
proximal tubular cell hypertrophy in vitro and partially
prevents the increase in kidney weight and extracellular
matrix expression in diabetic mice.
transforming growth factor-b1; nephropathy; proximal tu-
bule; glucose; collagen type IV; fibronectin; osmotic mini-
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DIABETIC RENAL HYPERTROPHY is a consistent finding in
the early stage of type 1 diabetes mellitus in humans
and in the streptozotocin-diabetes model (23, 25). In-
creased steady-state mRNA levels encoding type IV
collagen and fibronectin in the kidney are also features
of the early stages of diabetic nephropathy (9, 14, 22).
Diabetic renal hypertrophy is predominantly due to
tubular epithelial cell hypertrophy, which accounts for
the increase in whole kidney weight (16, 19, 20).
Hyperglycemia and other metabolic and hemodynamic
factors underlying the diabetic state are the principal
causes for the development of diabetic nephromegaly
(19, 25). In fact, recent in vitro studies provided evi-
dence that high ambient glucose per se can induce
proximal tubular epithelial cell hypertrophy (29, 33,
34) and increase the synthesis of extracellular matrix
components in these cells (3, 34).
Several key pieces of evidence have implicated the
TGF-b system as an etiologic agent in the genesis and
maintenance of diabetic renal hypertrophy (11, 30). In
an in vitro system, we have previously reported that
proximal tubular epithelial cells express significant
increments in TGF-b1 mRNA levels and bioactivity
when cultured in high glucose concentration (17). Fur-
thermore, we and others have demonstrated that
TGF-b1 mRNA and protein levels are significantly
increased in the kidney cortex after only a few days of
overt hyperglycemia in animal models of type 1 diabe-
tes mellitus (14, 21, 24). Direct evidence implicating the
TGF-b system in the pathogenesis of experimental
diabetic renal hypertrophy has derived from the results
of a short-term study whereby a neutralizing monoclo-
nal antibody directed against all three mammalian
isoforms of TGF-b was administered intraperitoneally
to streptozotocin-diabetic mice (22). Treatment with
the antibody totally prevented glomerular hypertrophy,
reduced the increment in kidney weight by ,50%, and
significantly attenuated the increase in renal mRNA
levels of a1(IV) collagen and fibronectin. However, the
individual contribution of the TGF-b1 isoform alone in
mediating the renohypertrophic effects of the diabetic
state could not be deciphered from these studies.
Recent advancements in biotechnology have made
possible the application of antisense oligodeoxynucleo-
tide (ODN) therapy in vivo to inhibit the function of a
specific protein or enzyme (4–6, 27). Inhibition of gene
expression by antisense ODNs relies on their ability to
bind complementary mRNA sequences and the preven-
tion of protein translation (26). The proximal tubule is a
suitable target for ODN therapy in vivo because it has
been previously demonstrated that circulating ODNs
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accumulate in the kidney, mainly in the proximal
tubule, in concentrations that are higher than in any
other organ (6, 18, 31). For example, therapy with
antisense ODNs against the sodium-phosphate cotrans-
porter suppressed phosphate uptake into the brush-
border membrane of the proximal tubule (13). Because
increased proximal tubular TGF-b1 expression may
mediate diabetic renal hypertrophy, we investigated
the effects of therapy with antisense TGF-b1 ODN on
the high-glucose-stimulated protein synthesis in proxi-
mal tubular cell culture and on diabetic renal hypertro-
phy in vivo. This allowed us to test the hypothesis that
increased activity of the renal TGF-b1 system in early
diabetes mellitus in mice contributes to renal hypertro-
phy in this disease.
METHODS
Proximal tubular cell culture. MCT is a murine proximal
tubular cell line that has been propagated in culture by SV-40
virus transformation (7). The cells demonstrate stable struc-
tural and functional features that are characteristic of differ-
entiated proximal tubular epithelial cells (7, 28). Cells were
cultured at 37°C in a humidified incubator with 5% CO2-95%
air and passaged twice every week by light trypsinization.
The growth media was DMEM (GIBCO-BRL) containing 5.5
mM D-glucose, 10% FCS, 100 U/ml penicillin, 100 µg/ml
streptomycin, and 2 mM glutamine.
Preparation of ODNs. We designed and synthesized 19-mer
ODNs that were phosphorothioate modified to increase stabil-
ity (Cancer Center, Univ. of Pennsylvania). The antisense
ODN encompasses the ATG of the murine TGF-b1 gene and
has the sequence 58-AGGGCGGCATGGGGGAGGC-38 (6.13
mg/µmol). The sense ODN, used as control, has the sequence
58-GCCTCCCCCATGCCGCCCT-38 (5.75 mg/µmol). Lyophi-
lized ODNs were resuspended in distilled water and then
diluted to give the required final concentration.
3[H]leucine incorporation. Incorporation of 3[H]leucine into
acid-precipitable proteins was used as a sensitive index of de
novo protein synthesis in MCT cells (29, 33, 34). Cells were
plated at 5 3 105 cells/well in 24-well plates (Nunc) in the
growth media. The next day, cells were rested in serum-free
medium for 24 h and then exposed for 48 h to either normal
(5.5 mM) or high (25 mM) D-glucose. Sense or antisense ODNs
(1 µM) were added to some of the wells. For the last 12 h of
culture, cells were pulsed with 5 µCi 3[H]leucine (142 Ci/
mmol, Amersham). Cell monolayers were washed twice with
ice-cold phosphate-buffered saline, precipitated in ice-cold
10% TCA, redissolved in 500 µl of 0.5 M NaOH10.1% Triton
X-100, and counted for b emissions. Additional plates of cells
exposed to the same experimental conditions were used to
obtain cell counts in a Coulter counter. Leucine incorporation
was expressed as counts per minute per 106 cells.
Diabetic mice. Diabetes was induced in 8-wk-old C57/bl
female mice by two consecutive intraperitoneal injections of
streptozotocin (200 mg·kg21 ·day21; Sigma Chemical) dis-
solved in 10 mM Na citrate, pH 5.5 (22). Nondiabetic mice
were injected with buffer alone. Once glycosuria was de-
tected, regular insulin (0.1–0.2 U) was administered subcuta-
neously every day to prevent ketonuria and maintain a
moderately elevated blood glucose concentration (22–28 mM).
Osmotic minipumps (model 2002, Alza) were implanted sub-
cutaneously in the flank of each mouse under sterile condi-
tions. The next day, diabetic and nondiabetic mice were
weight-matched to receive either sense or antisense ODNs.
The ODN delivery rate through the pump was 100 µg/day. At
the end of the experimental period, individual 24-h urine
collections were obtained. The animals were then weighed,
blood was collected, and the kidneys were harvested, weighed,
and immediately frozen in liquid nitrogen for RNA and
protein extraction. Kidney protein extracts were determined
in duplicate (Bio-Rad).
TGF-b1 ELISA. Total (latent 1 active) TGF-b1 levels were
measured in MCT-conditioned culture media, mouse plasma,
urine, and kidney protein extracts by using an ELISA kit
(Genzyme), as previously described (8, 22). Quiescent MCT
cells were cultured as described above. Cells were exposed for
48 h to DMEM containing either 5.5 or 25 mM D-glucose and
incubated in the presence of sense or antisense TGF-b1
ODNs. At the end of the incubation period conditioned media
were collected, centrifuged, and stored in 270°C. Samples of
media, plasma, or urine were acid activated to convert latent
into active TGF-b1 and to record detectable levels of TGF-b1.
Samples were activated with 1 N HCl for 60 min at 4°C
followed by neutralization with 1 N NaOH. Samples were
plated on microtiter plates coated with mouse monoclonal
anti-human TGF-b1 antibody and incubated at 37°C for 60
min. After being washed five times, wells were incubated with
a second horseradish peroxidase-conjugated polyclonal anti-
TGF-b1 antibody, and then the peroxidase reaction was
initiated. A standard curve was constructed by using serial
dilutions of human TGF-b1 (Genzyme), and TGF-b1 levels in
samples were compared with known standards and read as
nanograms per 106 cells. TGF-b1 levels in urine samples were
expressed per milligram of urinary creatinine, measured by a
colorimetric assay (Sigma Chemical). Total kidney levels of
TGF-b1 protein were expressed per milligram protein of
tissue extract.
Northern hybridization. Cultured MCT cells or frozen
kidneys were lysed and denatured in 4 M guanidinium
thiocyanate, 25 mM sodium citrate, pH 7.0, 0.5% sarcosyl,
and 0.1 M 2-mercaptoethanol (24, 32). RNA extraction was
performed as previously described. RNA from individual
samples (25 µg) were electrophoresed on a 1.2% agarose gel
containing 0.67 M formaldehyde, transferred by capillary
blotting to Gene-Screen nylon membrane (NEN Research
Products), and ultraviolet crosslinked. The cDNA probes
encoding murine a1(IV) collagen, fibronectin, and ribosomal
protein mrpL32 were as previously reported (12, 22). Hybrid-
ization and washing were performed as previously described
(8, 32). The membranes were autoradiographed with intensi-
fying screens (Kodak, Wilmington, DE) at 270°C for 1–4
days. Exposed films were scanned with a laser densitometer
(Hoefer Scientific Instruments), and mRNA levels were calcu-
lated relative to corresponding mrpL32. Measurements of
density in normal glucose media (5.5 mM) or in nondiabetic
mice treated with sense ODN were assigned a relative value
of 100%.
Statistical analysis. Data are presented as the means 6 SE
with n as the number of different experiments or the number
of animals per group. Groups were compared by analysis of
variance, and an unpaired t-test was used to compare indi-
vidual groups. A P value , 0.05 was considered significant.
RESULTS
Response of proximal tubular cells. Total TGF-b1
protein was measured by ELISA to test whether anti-
sense TGF-b1 ODN was able to reduce TGF-b1 synthe-
sis in MCT cells. As control, exposure of MCT cells to
high ambient glucose concentration (25 mM) for 48 h
without treatment with ODN, stimulated total TGF-b1
protein secretion into the culture media by ,50%
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compared with normal glucose concentration (5.5 mM)
(Fig. 1). Addition of 1 µM antisense TGF-b1 ODN
effectively reduced the high-glucose-induced increase
in TGF-b1 (Fig. 1). However, and as would be expected,
there was no inhibitory effect on TGF-b1 production
when MCT cells were exposed to sense ODN (Fig. 1).
We previously reported that high glucose inhibits
proximal tubular cell proliferation but induces hypertro-
phy (34). Neutralizing anti-TGF-b antibodies directed
against TGF-b1 and TGF-b2 prevented the antiprolifer-
ative effect of high glucose (17). To demonstrate that
the hypertrophic effect of high ambient glucose is
mediated by increased activity of the TGF-b1 system in
these cells, we tested whether antisense TGF-b1 ODN
is capable of reducing the high-glucose-stimulated leu-
cine incorporation. Figure 2 shows that MCT cells
without or with supplemental sense ODN displayed a
.2.2-fold increase in leucine incorporation when cul-
tured in high glucose for 48 h. However, the high-
glucose-stimulated incorporation was significantly at-
tenuated when antisense ODN (1 µM) was added to the
media (Fig. 2). In addition, antisense ODN (1 µM)
reduced the high-glucose-stimulated fibronectin mRNA
(relative to mrpL32) 1.8-fold to 1.3-fold, compared with
normal glucose media (n 5 3, P , 0.05). These results
suggest that autocrine production of TGF-b1 is respon-
sible, at least in part, for the stimulatory effect of high
glucose on protein synthesis and matrix expression in
MCT cells. It is also possible that the high-glucose-
stimulated protein synthesis and matrix expression
could be mediated partly by other isoforms of TGF-b
and/or by non-TGF-b pathways.
Response of diabetic hypertrophy. Table 1 displays
the body and kidney weights and the blood glucose
concentration after 10 days of ODN infusion in the four
groups of mice. Diabetic mice treated with either sense
or antisense ODNs had equivalently elevated blood
glucose concentration at the end of the study period
(Table 1). Body weight was similarly reduced in the
diabetic mice treated with either sense or antisense
ODNs. None of the animals died during the study. Total
kidney weight increased by 15.3% in diabetic mice
Fig. 1. Effect of oligodeoxynucleotides on transforming growth fac-
tor-b1 (TGF-b1) production. Confluent MCT cells were made quies-
cent for 24 h and then studied for an additional 48 h in serum-free
DMEM containing either 5.5 or 25 mM D-glucose, with or without
addition of sense and antisense TGF-b1 oligodeoxynucleotides (ODNs).
ELISA for total TGF-b1 protein secretion (latent 1 active) was
performed on conditioned media and was expressed per total cell
protein content. Normal glucose (hatched bar); high glucose (filled
bars). Values are means 6 SE. Cells grown in high glucose demon-
strate a significant increase in total TGF-b1 secretion compared with
cells grown in normal glucose (*P , 0.01 vs. corresponding normal
glucose; n 5 6). This increase in TGF-b1 by high glucose was partially
diminished by antisense TGF-b1 ODNs (**P , 0.05 vs. high glucose
alone or sense-treated cells grown in high glucose).
Fig. 2. Effect of ODN on 3[H]leucine incorporation. Confluent MCT
cells were made quiescent for 24 h and then studied for an additional
48 h in serum-free DMEM containing either 5.5 or 25 mM D-glucose,
with or without addition of sense and antisense TGF-b1 ODN.
Normal glucose (hatched bars); high glucose (filled bars). Leucine
incorporation was expressed as counts·min21 ·106 cells. Values are
for means 6 SE. High glucose significantly stimulated 3[H]leucine
incorporation compared with normal glucose. However, treatment
with antisense TGF-b1 ODNs partially diminished this stimulation
compared with high glucose alone or sense-treated cells. *P , 0.01 vs.
normal glucose. **P , 0.05 vs. high glucose alone or sense-treated
cells grown in high glucose; n 5 6.
Table 1. Profile of body and kidney weights and blood
glucose in normal and diabetic mice treated with sense
or antisense TGF-b1 oligodeoxynucleotides for 10 days
Mice n
Body
Wt, g
Kidney
Wt, mg
Blood
Glucose, mM
Nondiabetic
Sense 8 20.160.4 24067 7.560.2
Antisense 8 20.260.2 24663 7.360.4
Diabetic
Sense 8 17.960.3* 276614* 25.762.3*
Antisense 8 18.060.3* 26267*† 25.662.1*
Values are means 6 SE. TGF, transforming growth factor. *P ,
0.05 vs. nondiabetic. †P , 0.05 vs. sense-diabetic.
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treated with sense TGF-b1 ODN compared with nondia-
betic control mice (240 6 7 vs. 276 6 14 mg, respec-
tively, P , 0.05). In contrast, kidney weight in diabetic
mice treated with antisense TGF-b1 ODN was in-
creased by 6.5% only, compared with antisense ODN-
treated nondiabetic mice (Table 1). Thus the increment
in total kidney weight in antisense ODN-treated dia-
betic mice was less than one-half that of sense ODN-
treated diabetic mice. These results suggest that auto-
crine production of TGF-b1 is responsible, at least in
part, for the acute stimulatory effect of diabetes on
kidney weight in mice.
Light microscopy of the kidneys derived from the
different groups of mice revealed no pathological le-
sions in the different compartments (cortical intersti-
tial, glomerular, and vascular), and there were no
changes induced by the treatment with the oligonucleo-
tides. Tubular cell height appeared increased in the
kidney of diabetic mice compared with the normal
kidney but, there were no other perceptible changes
because the duration of the diabetic state was only 10
days.
Response of the renal TGF-b1 system in diabetic mice.
Plasma levels of TGF-b1 were not significantly differ-
ent between the normal and diabetic groups, suggest-
ing that the short duration of the diabetic state did not
increase circulating TGF-b1 (data not shown), confirm-
ing our previous report (22). In contrast, urinary levels
of total TGF-b1 protein (latent 1 active fractions) were
markedly stimulated in diabetic mice (sense ODN-
treated diabetic mice: 6.7 6 1.3 ng/mg creatinine vs.
sense ODN-treated nondiabetic controls: 1.1 6 0.3
ng/mg creatinine; P , 0.05). Treatment of diabetic mice
with antisense ODN reduced urinary TGF-b1 levels
only slightly and not significantly (5.9 6 1.2 ng/mg
creatinine). However, Fig. 3 demonstrates that the
markedly elevated TGF-b1 protein level in the kidney
extracts of diabetic mice was significantly attenuated
by treatment with antisense ODN (Fig. 3; 29% reduc-
tion in the increment of renal TGF-b1 protein com-
pared with sense ODN-treated diabetic mice). These
studies are consistent with the notion that the diabetic
state is characterized by increased renal production of
TGF-b1 and that systemic administration of antisense
TGF-b1 ODN is effective in attenuating this increment.
Response of matrix overexpression in diabetic kidney.
Figure 4, A and B, shows that the mRNA encoding
a1(IV) collagen in the kidney of diabetic mice treated
with sense ODN was increased by 70% compared with
sense ODN-treated nondiabetic mice after 10 days of
diabetes. Inhibition of renal TGF-b1 with antisense
ODN treatment was associated with significantly de-
creased overexpression of a1(IV) collagen mRNA; the
increment was only 24% in antisense ODN-treated
mice compared with sense ODN-treated mice (Fig. 4, A
and B). Figure 5, A and B, demonstrates similar
changes in renal fibronectin mRNA expression; the 46%
increase in mRNA level in sense-treated diabetic mice
was significantly reduced by antisense ODN treatment,
nearly to the level found in nondiabetic mice treated
with sense ODN. Thus inhibiting TGF-b1 activity in
the early phase of streptozotocin-induced diabetes mark-
edly attenuates the stimulation in gene expression of
the extracellular matrix molecules, type IV collagen
and fibronectin, in the mouse kidney. However, we
cannot exclude that other isoforms of TGF-b and/or
non-TGF-b pathways can be partly responsible for
increased matrix expression in the kidney.
DISCUSSION
Increased activity of the renal TGF-b system has
been implicated as an etiologic factor in the genesis and
maintenance of diabetic renal hypertrophy (22). We
sought to test this hypothesis by examining the effects
of therapy with antisense TGF-b1 ODN on the high-
glucose-mediated tubular epithelial cell hypertrophy in
vitro and on diabetic renal hypertrophy in vivo. Anti-
sense ODN suppressed the high-glucose-stimulated
TGF-b1 secretion and leucine incorporation in mouse
renal proximal tubular cells in culture. Short-term
continuous infusion of antisense ODN in streptozotocin-
induced diabetic mice significantly decreased renal
TGF-b1 protein levels and attenuated the increase in
kidney weight and extracellular matrix mRNA levels.
Our previous investigations in tissue culture have
shown that high glucose concentration in the culture
media of proximal tubule cells inhibits cell proliferation
(33, 34), induces cell hypertrophy (29, 34), and in-
creases TGF-b1 mRNA level and bioactivity (17). High
glucose concentration also stimulates collagen gene
transcription and secretion (33, 34). A neutralizing
anti-TGF-b antibody that is directed against TGF-b1
and TGF-b2 prevents the inhibitory effect of high
glucose on cell proliferation (17). Using specific anti-
Fig. 3. Effect of ODN on TGF-b1 protein in kidney extract. Nondia-
betic control mice and streptozotocin-diabetic mice were infused with
either sense (open bars) or antisense ODN (hatched bars) for 10 days
via osmotic minipumps. ELISA for total TGF-b1 protein content
(latent 1 active) was performed on kidney extracts and was ex-
pressed per total kidney protein content. Values are means 6 SE.
Note that the increase in renal TGF-b1 protein in diabetic mice (*P ,
0.01 vs. nondiabetic mice, n 5 8), was partially suppressed by
anti-sense TGF-b1 ODN (**P , 0.05 vs. sense-treated diabetic mice;
n 5 8).
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sense TGF-b1 ODN in the present study, we demon-
strate that autocrine production of TGF-b1 is respon-
sible, at least in part, for the stimulatory effect of high
glucose on protein synthesis and matrix expression in
proximal tubular cells. Our studies in tubular cells extend
the results of Kolm et al. (10), who used antisense
TGF-b1 ODN in cultured glomerular mesangial cells to
inhibit the high-glucose-mediated stimulation of fibro-
nectin and heparan sulfate proteoglycan production.
The experiments utilizing systemic infusion of anti-
sense TGF-b1 ODN in diabetic mice are the first to
exploit this technique. The tissue distribution after
administration of ODN through subcutaneous, intrader-
mal, or intraperitoneal routes, is similar to that of
intravenous injections (1). We administered ODN
through a single subcutaneous implantation of minios-
motic pumps in mice to release ODNs over a 10-day
period. The ODNs were phosphorothioate modified to
increase stability and to prevent rapid degradation.
The results of these experiments provide direct evi-
Fig. 4. Effects of ODN on renal collagen type IV gene expression.
Nondiabetic control mice (N) and streptozotocin-diabetic (D) mice
were infused with either sense (S, open bars) or antisense ODN (AS;
hatched bars) for 10 days via osmotic minipumps. A: representative
Northern blot of kidney RNA probed with cDNA encoding murine
a1(IV) (top) and mrpL32 as control (bottom). B: summary of densito-
metric analysis of ratios for a1(IV)/mrpL32 mRNA levels in 4
treatment groups. Values are means 6 SE. Note that the increase in
renal a1(IV) mRNA in diabetic mice (*P , 0.01 vs. nondiabetic mice;
n 5 8) was partially suppressed by antisense TGF-b1 ODN (**P ,
0.05 vs. sense-treated diabetic mice; n 5 8).
Fig. 5. Effects of ODN on renal fibronectin gene expression. Nondia-
betic control mice (N) and streptozotocin-diabetic (D) mice were
infused with either sense (S; open bars) or antisense ODN (AS;
hatched bars) for 10 days via osmotic minipumps. A: representative
Northern blot of kidney RNA probed with cDNA encoding murine
fibronectin (top) and mrpL32 as control (bottom). B: summary of
densitometric analysis of ratios for fibronectin/mrpL32 mRNA levels
in the 4 treatment groups. Values are means 6 SE. Note that the
increase in renal fibronectin mRNA in diabetic mice (*P , 0.01 vs.
nondiabetic mice; n 5 8) was virtually prevented by antisense
TGF-b1 ODN (**P , 0.05 vs. sense-treated diabetic mice; n 5 8).
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dence implicating TGF-b1 specifically in the pathogen-
esis of diabetic renal hypertrophy. The increment in
total kidney weight in antisense ODN-treated diabetic
mice was only one-half that of sense ODN-treated
diabetic mice. Additionally, treatment of diabetic mice
with antisense ODN partially but significantly de-
creased kidney TGF-b1 protein levels and attenuated
the increase in the mRNA levels encoding a1(IV) colla-
gen and fibronectin in the kidney. Thus it can be
concluded that the increased production of TGF-b1 in
the diabetic kidney is responsible, at least in part, for
the acute stimulatory effect of the diabetic state on
renal hypertrophy and the accompanying overexpres-
sion of extracellular matrix proteins. The persistently
elevated urinary TGF-b1 levels, despite antisense ODN
treatment (as opposed to the significant decrement in
total kidney TGF-b1 levels), may relate to the possibil-
ity that urinary TGF-b1 originates from multiple
sources (the circulation, glomeruli, tubules), whereas
ODN therapy targets effectively only tubules.
In a previous short-term in vivo study we demon-
strated that intraperitoneal administration of a neutral-
izing monoclonal antibody directed against the three
mammalian isoforms of TGF-b (TGF-b1, TGF-b2, and
TGF-b3) into streptozotocin-diabetic mice prevented
glomerular hypertrophy, reduced the increment in kid-
ney weight, and significantly attenuated the increase
in renal mRNA levels of a1(IV) collagen and fibronectin
(22). It was unclear what the contribution was of each
of the three isoforms to the diabetic changes in the
kidney (22). Using specific reagents such as antisense
ODN directed at the TGF-b1 sequence, as was done in
the present study, has provided evidence that increased
production of TGF-b1 in the diabetic kidney is respon-
sible, at least in large part, for mediating diabetic renal
hypertrophy.
The present study supports the feasibility and the
efficacy of delivering specific ODNs to the kidney.
Inhibition of gene expression by antisense ODN relies
on its ability to bind complementary mRNA sequences
and prevent translation (4–6, 27). The proximal tubule
is a suitable target for ODN therapy in vivo because
circulating ODNs accumulate in the kidney, mainly in
the proximal tubule, in significantly high concentra-
tions (6, 18, 31). Because increased proximal tubular
TGF-b1 expression may mediate diabetic renal hyper-
trophy, systemic infusions of ODN are expected to
accumulate in the proximal tubule where they can
target TGF-b1 production. Using intravenous adminis-
tration of 32P-labeled ODN, Rappaport et al. (15) readily
detected the presence of ODN in Bowman’s space, the
proximal tubular lumen, and tubular epithelial cells
where the ODN accumulated. In addition, Oberbauer
et al. (13) demonstrated that antisense ODN directed
at the sodium-phosphate cotransporter suppressed
phosphate uptake across the brush-border membrane
in the proximal tubule. Targeting other cells of the
kidney may require different delivery systems. Gene
transfer of TGF-b1 antisense ODN to the glomerulus
has been previously attempted by the hemagglutinat-
ing virus of Japan liposome method delivered through
the arterial supply of the kidney (2); a successful
reduction of matrix molecule overexpression in the
glomerulus was therefore achieved in a model of glo-
merulonephritis. Targeting TGF-b1 production in the
glomerulus rather than the tubules in the diabetic
state may require a similar approach as that used by
Akagi and co-workers (2).
The partial effects of antisense ODN observed in this
study may have many explanations, including the
relatively low dose (which should avoid nonspecific
effects), the role of other isoforms of TGF-b and/or
non-TGF-b pathways in mediating diabetic hypertro-
phy, and the nonhomogeneous distribution of ODN in
the kidney, which preferentially favors tubular uptake.
In conclusion, antisense TGF-b1 ODN attenuates the
high-glucose-induced hypertrophy of proximal tubular
cells in vitro. In addition, short-term treatment with
antisense TGF-b1 ODN given in continuous infusion
via osmotic minipumps is efficacious in decreasing
renal TGF-b1 production and attenuating kidney hyper-
trophy and the increase in extracellular matrix expres-
sion in diabetic mice.
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